The first export of tetravalent influenza vaccine from Wuhan Institute of Biological Products of China to Africa

On the morning of October 19th, the first batch of tetravalent influenza virus split vaccine exported to Africa by China Biological Wuhan Institute of Biological Products was sent to Kenya. This vaccine is the first influenza vaccine registered in Kenya and exported for sale by China National Pharmaceutical Group's China Biotechnology

On the morning of October 19th, the first batch of tetravalent influenza virus split vaccine exported to Africa by China Biological Wuhan Institute of Biological Products was sent to Kenya. This vaccine is the first influenza vaccine registered in Kenya and exported for sale by China National Pharmaceutical Group's China Biotechnology.

In December 2022, the independently developed tetravalent influenza virus split vaccine by Wuhan Institute of Biological Products was successfully registered in Kenya; In August 2023, the product sales contract was successfully signed and the product export work was carried out.

Influenza is an acute respiratory infectious disease caused by the influenza virus. According to the World Health Organization, approximately 600 million people worldwide are infected with the influenza virus each year, with up to 250000 to 500000 deaths. Vaccination against influenza is the most cost-effective and effective preventive measure. The influenza vaccine prepared by Wuhan Institute of Biological Products adopts a patented process that does not contain antibiotics or preservatives. It is the first clinical trial conducted in China for elderly people over 60 years old and has obtained data support. The product has high purity, low impurity content, and good safety and effectiveness.

The overseas export of tetravalent influenza virus split vaccine of China Biological Wuhan Institute of Biological Products is a fruitful result of the vigorous development of international cooperation along the "the Belt and Road", and also a specific example of promoting the high-quality development of the "the Belt and Road". China's vaccine will continue to contribute to the global war and make positive contributions to building a community with a shared future for mankind.

[Source: China Biotech]

Declaration: The copyright of this article belongs to the original author. If there is any source error or infringement of your legitimate rights and interests, you can contact us through email, and we will promptly handle it. Email address: [email protected]

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])